Lymphocele Outcomes After Renal Transplantations Performed by an Experienced Surgeon: Is Meticulously Performed Surgery and Experience Adequate to Prevent Lymphocele?

20 February 2024 : Original article

Nurettin Ay^1ABCDEF*, Vahhac Alp^1B, Recai Duymuş^2BD, Sedat Çetin^3BD

DOI: 10.12659/AOT.942656

Ann Transplant 2024; 29:e942656

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 3 Patient, surgical, preoperative, and postoperative variables.

Characteristic	All patients n=315	Nonlymphocele group 233 (74%)	Lymphocele group 82 (26%)	P value
				0.419
Preemptive	96 (30.5%)	69 (29.6%)	27 (32.9%)
HD	203 (64.4%)	150 (64.4%)	53 (64.6%)
CAPD	16 (5.1%)	14 (6%)	2 (2.4%)
	5 (0–36)	7 (0–36)	3 (0–12)
	41 (37–45)	41 (37–45)	41 (37–44)	0.465
	35 (32–39)	35 (32–39)	34 (31–38)	0.187
	1.39 (1.1–1.64)	1.38 (1.09–1.63)	1.39 (1.12–1.77)	0.475
	18 (5.7%)	17 (7.3%)	1 (1.2%)
				0.52
Acute cellular rejection	2 (0.6%)	2 (8.6%)	0
Acute humoral rejection	4 (1.2%)	3 (1.3%)	1 (1.2%)
FSGS recurrence	2 (0.6%)	2 (8.6%)	0
MNP recurrence	2 (0.6%)	2 (8.6%)	0
CAN	6 (1.7%)	6 (1.7%)	0
BKVN	2 (0.6%)	2 (8.6%)	0
	0.157
Live	272 (86.3%)	198 (85%)	74 (90.2%)
Cadaveric	43 (13.7%)	35 (15%)	8 (9.85)
				0.76
Open	107 (39.3%)	79 (39.9%)	28 (37.8%)
Laparoscopic	165 (60.6%)	119 (60.1%)	46 (62.2%)
	44.4±22.2	42.3±23.6	53.7±15.8	0.2
				1.00
Right	101 (32.1%)	75 (32.2%)	26 (31.7%)
Left	214 (67.9%)	158 (67.8%)	56 (68.3%)
	9 (7–14)	9 (7–17)	9 (7–13)	0.287
	7/150 (4.7%)	6/111 (5.4%)	1/49 (2%)	0.677
HD – hemodialysis; CAPD – continuous ambulatory peritoneal dialysis; FSGS – focal segmental glomerulosclerosis; MNP – membranous nephropathy; CAN – chronic allograft nephropathy; BKVN – BK virus nephropathy; De novo DSA – de novo donor-specific antigen/Data from 150 cases are available: Dialysis durations of patients on HD and CAPD.

Back to the Article